Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort

Background: Rituximab has become one of the first-line therapies for the treatment of moderate and high-risk primary membranous nephropathy (pMN). We retrospectively reviewed 95 patients with pMN who received rituximab therapy and focused on the therapeutic effects and safety of this therapy in a Ch...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in medicine 2021-05, Vol.8, p.663680-663680
Main Authors: Gao, Shuang, Cui, Zhao, Wang, Xin, Zhang, Yi-miao, Wang, Fang, Cheng, Xu-yang, Meng, Li-qiang, Zhou, Fu-de, Liu, Gang, Zhao, Ming-hui
Format: Article
Language:English
Subjects:
anti-PLA2R antibody
CD20 monoclonal antibody
first line treatment
Medicine
primary membranous nephropathy
rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Rituximab has become one of the first-line therapies for the treatment of moderate and high-risk primary membranous nephropathy (pMN). We retrospectively reviewed 95 patients with pMN who received rituximab therapy and focused on the therapeutic effects and safety of this therapy in a Chinese cohort. Methods: Ninety-five consecutive patients with pMN diagnosed by kidney biopsy received rituximab and were followed up for >6 months. Four weekly doses of rituximab (375 mg/m 2 ) was adopted as the initial administration. Repeated single infusions were administrated to maintain B cell depletion levels of
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2021.663680